Formation Bio raises $600 million for AI-driven drug development expansion

Traders Union
All News
Business & Wealth
Companies
Formation Bio $600M AI expansion

Highlights

Formation Bio raised $600 million from investors including a16z, Sequoia Capital, and Thrive Capital to expand AI-driven drug development.
CEO Ben Liu claims leveraging AI and centralized operations could cut drug development costs by up to 50%, supporting ambitions to rival Eli Lilly or Sanofi.
Formation Bio's hub-and-spoke model focuses on acquiring drug programs and managing them through centralized, AI-optimized processes to address biotech industry inefficiencies.

Funding plan and operating model

As reported by Axios, Formation Bio is using the new capital to fund drug development efforts and tackle bottlenecks that continue to slow the biotech industry.

The startup is backed by investors including a16z, Sequoia Capital and Thrive Capital, and it says the funding supports an ambition to build a large pharmaceutical company comparable to Eli Lilly or Sanofi. Chief executive Ben Liu says clinical research processes need to change, arguing that as much as 50% of drug development costs can be cut through stronger centralization and the use of AI.

Formation Bio plans to purchase molecules and drug programs and then help advance their development through a hub-and-spoke structure designed to improve efficiency. The approach is intended to streamline costs while increasing output across its pipeline.

Implications for biotech productivity

The strategy reflects a broader push across biotech to apply AI not only to discovery but also to the operational side of drug development, where delays and fragmented execution often drive up costs. By focusing on central coordination, Formation Bio is positioning itself around the idea that process improvements can be as important as scientific breakthroughs in scaling the business.

If the model works as intended, it could offer a different route to growth from the traditional biotech playbook of advancing a narrow set of in-house assets. The company is instead betting that acquiring external programs and managing them through a more standardized system can help address industry inefficiencies and support larger-scale pharmaceutical expansion.

Our earlier article on AstraZeneca’s AI drug discovery collaboration with insitro highlighted a multi-year partnership aimed at improving early-stage research in hard-to-treat liver and heart diseases, including MASH and cardiomyopathies. We noted that insitro’s “Virtual Human” platform is designed to help identify targets and advance them to development-candidate stage, underscoring a broader industry push to use AI to speed up R&D and reduce trial-and-error in discovery.

This material may contain third-party opinions, none of the data and information on this webpage constitutes investment advice according to our Disclaimer. While we adhere to strict Editorial Integrity, this post may contain references to products from our partners.